Aura Biosciences: 2 Positive Bel-Sar Data Releases Brings Shareholder Value [Seeking Alpha]
Aura Biosciences, Inc. (AURA)
Company Research
Source: Seeking Alpha
Play 18min Summary The positive end of phase 2 study data was achieved using bel-sar for the treatment of patients with intermediate lesions and small choroidal melanoma. The global uveal melanoma treatment market is expected to reach $2.4 billion by 2033. Positive data was reported from the phase 1 study, using bel-sar for the treatment of patients with non-muscle invasive bladder cancer. The global non-muscle invasive bladder cancer market is expected to reach $5.5 billion by 2031. Looking for a portfolio of ideas like this one? Members of Biotech Analysis Central get exclusive access to our subscriber-only portfolios. Learn More » SolStock Aura Biosciences, Inc. NASDAQ: AURA ) has been able to advance its pipeline with great clinical success in the last several months. That's because it has been able to report positive results from two studies using its virus-like drug This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmac
Show less
Read more
Impact Snapshot
Event Time:
AURA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AURA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AURA alerts
High impacting Aura Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
AURA
News
- Aura Biosciences, Inc. (NASDAQ: AURA) had its "buy" rating re-affirmed by analysts at Cowen Inc.MarketBeat
- Aura Biosciences, Inc. (NASDAQ: AURA) had its price target raised by analysts at Scotiabank from $20.00 to $23.00. They now have a "sector outperform" rating on the stock.MarketBeat
- Aura Biosciences, Inc. (NASDAQ: AURA) had its price target raised by analysts at BTIG Research from $21.00 to $24.00. They now have a "buy" rating on the stock.MarketBeat
- Aura Biosciences, Inc. (NASDAQ: AURA) had its price target raised by analysts at HC Wainwright from $21.00 to $22.00. They now have a "buy" rating on the stock.MarketBeat
- Multiple Clinical Complete Responses Demonstrated Following Single Low Dose Administration of Bel-sar in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC) in Ongoing Phase 1 TrialGlobeNewswire
AURA
Earnings
- 5/9/24 - Beat
AURA
Sec Filings
- 10/29/24 - Form 144
- 10/29/24 - Form 144
- 10/29/24 - Form 144
- AURA's page on the SEC website